Advertisement

AIDS and Behavior

, Volume 23, Issue 2, pp 406–417 | Cite as

Multi-level Determinants of Clinic Attendance and Antiretroviral Treatment Adherence Among Fishermen Living with HIV/AIDS in Communities on Lake Victoria, Uganda

  • K. M. SileoEmail author
  • R. K. Wanyenze
  • W. Kizito
  • E. Reed
  • S. K. Brodine
  • H. Chemusto
  • W. Musoke
  • B. Mukasa
  • S. M. Kiene
Original Paper

Abstract

This cross-sectional study assessed determinants of HIV clinic appointment attendance and antiretroviral treatment (ART) adherence among 300 male fisherfolk on ART in Wakiso District, Uganda. Multi-level factors associated with missed HIV clinic visits included those at the individual (age, AOR = 0.98, 95% CI 0.97–0.99), interpersonal (being single/separated from partner, AOR: 1.25, 95% CI 1.01–1.54), normative (anticipated HIV stigma, AOR: 1.55, 95% CI 1.05–2.29) and physical/built environment-level (travel time to the HIV clinic, AOR: 1.11, 95% CI 1.02–1.20; structural-barriers to ART adherence, AOR: 1.27, 95% CI 1.04–1.56; accessing care on a landing site vs. an island, AOR: 1.35, 95% CI 1.08–1.67). Factors associated with ART non-adherence included those at the individual (age, β: − 0.01, η2 = 0.03; monthly income, β: − 0.01, η2 = 0.02) and normative levels (anticipated HIV stigma, β: 0.10, η2 = 0.02; enacted HIV stigma, β: 0.11, η2 = 0.02). Differentiated models of HIV care that integrate stigma reduction and social support, and reduce the number of clinic visits needed, should be explored in this setting to reduce multi-level barriers to accessing HIV care and ART adherence.

Keywords

HIV/AIDS ART adherence HIV care engagement Key populations Fisherfolk Uganda 

Notes

Acknowledgements

We thank the research participants for their time and participation. We also are grateful to Mildmay Uganda outreach teams and clinic staff for supporting this study. We thank Rose Naigino and Rose Kisa for their help supporting this study. This manuscript is part of K. Sileo’s doctoral dissertation. We thank Jennifer A. Wagman and Jamila K. Stockman for their feedback on this manuscript.

Funding

The GloCal Health Fellowship from the National Institute of Health Fogarty International Center and the University of California Global Health Institute awarded to K. Sileo supported this study (NIH/FIC 5R25TW009343-05). K. Sileo was also supported by a T32 Predoctoral Fellowship Award on Substance Abuse, HIV, and Related Infections from the National Institute of Drug Abuse T32 DA023356, PI: Steffanie Strathdee.

Compliance with Ethical Standards

Conflict of interest

We have no conflicts of interest to disclose.

Ethical Approval

All procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Asiki G, Mpendo J, Abaasa A, Agaba C, Nanvubya A, Nielsen L, et al. HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Dis. 2011;87(6):511–5.Google Scholar
  2. 2.
    Seeley J, Nakiyingi-Miiro J, Kamali A, Mpendo J, Asiki G, Abaasa A, et al. High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis. 2012;39(6):433–9.Google Scholar
  3. 3.
    Opio A, Muyonga M, Mulumba N. HIV sero behavioral survey in fishing communities of the Lake Victoria basin of Uganda. Stockholm: SIDA, MOH, AMREF; 2011.Google Scholar
  4. 4.
    Chang LW, Grabowski MK, Ssekubugu R, Nalugoda F, Kigozi G, Nantume B, et al. Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study. Lancet. 2016;3(3):8.Google Scholar
  5. 5.
    UNAIDS. Country facts: UGANDA 2016. UNAIDS; 2016. http://www.unaids.org/en/regionscountries/countries/uganda.
  6. 6.
    The World Health Organization (WHO). Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015.Google Scholar
  7. 7.
    Uganda Ministry of Health. Consolidated Guidelines for Prevention and Treatment of HIV in Uganda. Kampala: MOH; 2016.Google Scholar
  8. 8.
    World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2013.Google Scholar
  9. 9.
    Shand T, Thomson-de Boor H, van den Berg W, Peacock D, Pascoe L. The HIV blind spot: men and HIV testing, treatment and care in sub-Saharan Africa. IDS Bull. 2014;45(1):53–60.Google Scholar
  10. 10.
    Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health. 2011;16(7):828–9.Google Scholar
  11. 11.
    Tromp N, Michels C, Mikkelsen E, Hontelez J, Baltussen R. Equity in utilization of antiretroviral therapy for HIV-infected people in South Africa: a systematic review. Int J Equity Health. 2014;13(1):1–17.Google Scholar
  12. 12.
    Brofenbrenner U. Toward an experimental ecology of human development. Am Psychol. 1977;32:513–31.Google Scholar
  13. 13.
    McLeroy KRBD, Steckler A, Glanz K. A, An ecological perspective on health promotion programs. Health Educ Q. 1988;15(4):351–77.Google Scholar
  14. 14.
    Stokols D. Establishing and maintaining healthy environments: toward a social ecology of health promotion. Am Psychol. 1992;47(1):6–22.Google Scholar
  15. 15.
    Kaufman M, Cornish F, Zimmerman R, Johnson B. Health behavior change models for HIV prevention and AIDS care: practical recommendations for a multi-level approach. J Acquir Immune Defic Syndr. 2014;66:S250–8.Google Scholar
  16. 16.
    Castro EM, Santiago LE, Jiménez JC, Dávila-Vargas D, Rosal MC. A social-ecological view of barriers and facilitators for HIV treatment adherence: interviews with Puerto Rican HIV patients. PLoS ONE. 2015;10(9):e0125582.Google Scholar
  17. 17.
    Berger MB, Sullivan KA, Parnell HE, Keller J, Pollard A, Cox ME, et al. Barriers and facilitators to retaining and reengaging HIV clients in care. J Int Assoc Provid AIDS Care. 2015;15(6):486–93.Google Scholar
  18. 18.
    Hoffmann CJ, Mabuto T, McCarthy K, Maulsby C, Holtgrave DR. A framework to inform strategies to improve the HIV care continuum in low- and middle-income countries. AIDS Educ Prevent. 2016;28(4):351–64.Google Scholar
  19. 19.
    Hornschuh S, Dietrich JJ, Tshabalala C, Laher F. Antiretroviral treatment adherence: knowledge and experiences among adolescents and young adults in Soweto, South Africa. AIDS Res Treat. 2017;5192516.  https://doi.org/10.1155/2017/5192516.
  20. 20.
    Marcellin F, Abé C, Loubière S, Boyer S, Blanche J, Koulla-Shiro S, et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS. 2009;15(23):1015–9.Google Scholar
  21. 21.
    Nyanzi-Wakholi B, Medina Lara A, Munderi P. Gilks C, on behalf of the DTT. The charms and challenges of antiretroviral therapy in Uganda: the DART experience. AIDS Care. 2012;24(2):137–42.Google Scholar
  22. 22.
    Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16:18588.Google Scholar
  23. 23.
    Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51(2):135–9.Google Scholar
  24. 24.
    Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010;24(14):2263–70.Google Scholar
  25. 25.
    Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, Abrahams M, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS ONE. 2011;6(2):e14684.Google Scholar
  26. 26.
    Wang B, Losina E, Stark R, Munro A, Walensky RP, Wilke M, et al. Loss to follow-up in a community clinic in South Africa–roles of gender, pregnancy and CD4 count. S Afr Med J. 2011;101(4):253–7.Google Scholar
  27. 27.
    Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS ONE. 2010;5(5):e10584.Google Scholar
  28. 28.
    Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health. 2009;14(7):722–31.Google Scholar
  29. 29.
    Tumwesigye NM, Atuyambe L, Wanyenze RK, Kibira SP, Li Q, Wabwire-Mangen F, et al. Alcohol consumption and risky sexual behaviour in the fishing communities: evidence from two fish landing sites on Lake Victoria in Uganda. BMC Public Health. 2012;12:12.Google Scholar
  30. 30.
    Smolak A. A meta-analysis and systematic review of HIV risk behavior among fishermen. AIDS Care. 2013;26(3):282–91.Google Scholar
  31. 31.
    Kiwanuka N, Ssetaala A, Nalutaaya A, Mpendo J, Wambuzi M, Nanvubya A, et al. High Incidence of HIV-1 infection in a general population of fishing communities around Lake Victoria, Uganda. PLoS ONE. 2014;9(5):e94932.Google Scholar
  32. 32.
    Sileo KM, Simbayi LC, Abrams A, Cloete A, Kiene SM. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: event-level findings from a daily diary study. Drug Alcohol Depend. 2016;167:103–11.Google Scholar
  33. 33.
    Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180.Google Scholar
  34. 34.
    Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, Namagala E, et al. Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: a randomized controlled trial. AIDS Behav. 2011;15(8):1795–802.Google Scholar
  35. 35.
    Nachega JB, Knowlton AR, Deluca A, Schoeman JH, Watkinson L, Efron A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study. J Acquir Immune Defic Syndr. 2006;43:S127–33.Google Scholar
  36. 36.
    Allison EH, Seeley JA. HIV and AIDS among fisherfolk: a threat to ‘responsible fisheries’? Fish Fish. 2004;5(3):215–34.Google Scholar
  37. 37.
    Seeley JA, Allison EH. HIV/AIDS in fishing communities: challenges to delivering antiretroviral therapy to vulnerable groups. AIDS Care. 2005;17(6):688–97.Google Scholar
  38. 38.
    Seeley J, Tumwekwase G, Grosskurth H. Fishing for a living but catching HIV: AIDS and changing patterns of the organization of work in fisheries in Uganda. Anthopol Work Rev. 2009;30(2):66–76.Google Scholar
  39. 39.
    Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14:231.Google Scholar
  40. 40.
    Bogart LM, Naigino R, Maistrellis E, Wagner GJ, Musoke W, Mukasa B, et al. Barriers to linkage to HIV care in Ugandan fisherfolk communities: a qualitative analysis. AIDS Behav. 2016;20(10):2464–76.Google Scholar
  41. 41.
    Bogart LM, Wagner GJ, Musoke W, Naigino R, Linnemayr S, Maistrellis E, et al. A comparison of home-based versus outreach event-based community HIV testing in Ugandan fisherfolk communities. AIDS Behav. 2017;21(2):547–60.Google Scholar
  42. 42.
    Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16:18640.Google Scholar
  43. 43.
    Bonnington O, Wamoyi J, Ddaaki W, Bukenya D, Ondenge K, Skovdal M, et al. Changing forms of HIV-related stigma along the HIV care and treatment continuum in sub-Saharan Africa: a temporal analysis. Sex Transm Infect. 2017;93(3):e052975.Google Scholar
  44. 44.
    Tabatabai J, Namakhoma I, Tweya H, Phiri S, Schnitzler P, Neuhann F. Understanding reasons for treatment interruption amongst patients on antiretroviral therapy–a qualitative study at the Lighthouse Clinic, Lilongwe, Malawi. Glob Health Action. 2014;30(2):24795.Google Scholar
  45. 45.
    Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS Patient Care STDs. 2014;28(2):98–105.Google Scholar
  46. 46.
    Treves-Kagan S, Steward WT, Ntswane L, Haller R, Gilvydis JM, Gulati H, et al. Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa. BMC Public Health. 2016;16(1):87.Google Scholar
  47. 47.
    Wyrod R. Masculinity and the persistence of AIDS stigma. Cult Health Sex. 2011;13(4):443–56.Google Scholar
  48. 48.
    Mburu G, Ram M, Siu G, Bitira D, Skovdal M, Holland P. Intersectionality of HIV stigma and masculinity in eastern Uganda: implications for involving men in HIV programmes. BMC Public Health. 2014;14:1061.Google Scholar
  49. 49.
    Sileo K, Kintu M, Chanes-Mora P, Kiene S. “Such behaviors are not in my home village, I got them here”: a qualitative study of the influence of contextual factors on alcohol and HIV risk behaviors in a fishing community on Lake Victoria, Uganda. AIDS Behav. 2016;20(3):537–47.Google Scholar
  50. 50.
    Nunan F. Mobility and fisherfolk livelihoods on Lake Victoria: implications for vulnerability and risk. Geoforum. 2010;41(5):776–85.Google Scholar
  51. 51.
    Kwena ZA, Camlin CS, Shisanya CA, Mwanzo I, Bukusi EA. Short-term mobility and the risk of HIV infection among married couples in the fishing communities along Lake Victoria, Kenya. PLoS ONE. 2013;8(1):e54523.Google Scholar
  52. 52.
    Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-saharan africa and north america: a meta-analysis. JAMA. 2006;296(6):679–90.Google Scholar
  53. 53.
    Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010;5(1):70–7.Google Scholar
  54. 54.
    Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53(3):405–11.Google Scholar
  55. 55.
    Croome N, Ahluwalia M, Hughes LD, Abas M. Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa. AIDS (London, England). 2017;31(7):995–1007.Google Scholar
  56. 56.
    Muhamadi L, Nsabagasani X, Tumwesigye MN, Wabwire-Mangen F, Ekström A-M, Peterson S, et al. Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy in eastern Uganda. Health Policy. 2010;97(2):187–94.Google Scholar
  57. 57.
    Colvin CJ, Konopka S, Chalker JC, Jonas E, Albertini J, Amzel A, et al. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women. PLoS ONE. 2014;9(10):e108150.Google Scholar
  58. 58.
    Dovel KYS, Watkins S, Poulin M. Men’s heightened risk of AIDS-related death: the legacy of gendered HIV testing and treatment strategies. AIDS. 2015;29:1123–5.Google Scholar
  59. 59.
    The World Health Organization (WHO). The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. Geneva: WHO; 2001.Google Scholar
  60. 60.
    Martinez P, Andia I, Emenyonu N, Hahn JA, Hauff E, Pepper L, et al. Alcohol use, depressive symptoms and the receipt of antiretroviral therapy in Southwest Uganda. AIDS Behav. 2008;12(4):605–12.Google Scholar
  61. 61.
    Earnshaw VA, Smith LR, Chaudoir SR, Amico KR, Copenhaver MM. HIV stigma mechanisms and well-being among PLWH: a Test of the hiv stigma framework. AIDS Behav. 2013;17(5):1785–95.Google Scholar
  62. 62.
    Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12(3):255–66.Google Scholar
  63. 63.
    Antelman G, Smith Fawzi MC, Kaaya S, Mbwambo J, Msamanga GI, Hunter DJ, et al. Predictors of HIV-1 serostatus disclosure: a prospective study among HIV-infected pregnant women in Dar es Salaam, Tanzania. AIDS. 2001;15(14):1865–74.Google Scholar
  64. 64.
    Broadhead WE, Gehlbach SH, Gruy FVD, Berton HK. The duke-unc functional social support questionnaire: measurement of social support in family medicine patients. Med Care. 1988;26(7):709–23.Google Scholar
  65. 65.
    Epino HM, Rich ML, Kaigamba F, Hakizamungu M, Socci AR, Bagiruwigize E, et al. Reliability and construct validity of three health-related self-report scales in HIV-positive adults in rural Rwanda. AIDS Care. 2012;24(12):1576–83.Google Scholar
  66. 66.
    Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–71.  https://doi.org/10.1097/QAD.0b013e32802e6bfa.Google Scholar
  67. 67.
    Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, et al. Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS ONE. 2014;9(8):e104178.Google Scholar
  68. 68.
    Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr. 2007;46(4):402–9.Google Scholar
  69. 69.
    Uganda MOH. Addendum to the National Antiretroviral Treatment Guidelines. Kampala: Uganda Ministry of Health; 2013.Google Scholar
  70. 70.
    International AIDS Society (IAS). Differentiated care for HIV: a decision framework for antiretroviral. Available from:http://www.differentiatedcare.org/Portals/0/adam/Content/yS6M-GKB5EWs_uTBHk1C1Q/File/DecisionFramework.pdf. 2016.
  71. 71.
    Tsai AC, Bangsberg DR, Bwana M, Haberer JE, Frongillo EA, Muzoora C, et al. How does antiretroviral treatment attenuate the stigma of HIV? evidence from a cohort study in rural Uganda. AIDS Behav. 2013;17(8):2725–31.Google Scholar
  72. 72.
    Stangl AL, Lloyd JK, Brady LA, Holland CE, Baral S. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS Soc. 2013;16(2):18734.Google Scholar
  73. 73.
    Tshabalala J, Visser M. Developing a cognitive behavioural therapy model to assist women to deal with HIV and stigma. South Afr J Psychol. 2011;41(1):17–28.Google Scholar
  74. 74.
    Takada S, Weiser SD, Kumbakumba E, Muzoora C, Martin JN, Hunt PW, et al. The dynamic relationship between social support and HIV-related stigma in rural Uganda. Ann Behav Med. 2014;48(1):26–37.Google Scholar
  75. 75.
    Hickey MDSC, Omollo D, Mattah B, Fiorella KJ, Geng EH, Bacchetti P, Blat C, Ouma GB, Zoughbie D, Tessler RA, Salmen MR, Campbell H, Gandhi M, Shade S, Njoroge B, Bukusi EA, Cohen CR. Implementation and operational research: pulling the network together: quasiexperimental trial of a patient-defined support network intervention for promoting engagement in HIV care and medication adherence on Mfangano Island, Kenya. J Acquir Immune Defic Syndr. 2015;69(4):e127–34.Google Scholar
  76. 76.
    O’Laughlin KN, Wyatt MA, Kaaya S, Bangsberg DR, Ware NC. How treatment partners help: social analysis of an African adherence support intervention. AIDS Behav. 2012;16(5):1308–15.Google Scholar
  77. 77.
    Prust ML, Banda CK, Nyirenda R, Chimbwandira F, Kalua T, Jahn A, et al. Multi-month prescriptions, fast-track refills, and community ART groups: results from a process evaluation in Malawi on using differentiated models of care to achieve national HIV treatment goals. J Int AIDS Soc. 2017;20(Supplement 4):21650.Google Scholar
  78. 78.
    McCarthy EA, Subramaniam HL, Prust ML, Prescott MR, Mpasela F, Mwango A, et al. Quality improvement intervention to increase adherence to ART prescription policy at HIV treatment clinics in Lusaka, Zambia: a cluster randomized trial. PLoS ONE. 2017;12(4):e0175534.Google Scholar
  79. 79.
    Ssonko C, Gonzalez L, Mesic A, Silveira de Fonesca M, Achar J, Safar N, et al. Delivering HIV care in challenging operating environments: the MSF experience towards differentiated models of care for settings with multiple basic health care needs. Journal of the International AIDS Society; Vol 20 Supplement 4 (2017). 2017.Google Scholar
  80. 80.
    UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.Google Scholar
  81. 81.
    World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendation for a Public Health Approach. 2nd ed. Geneva: WHO; 2016.Google Scholar
  82. 82.
    Maheu-Giroux M, Vesga JF, Diabaté S, Alary M, Baral S, Diouf D, et al. Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d’Ivoire: insights from mathematical modeling. PLOS Med. 2017;14(6):e1002321.Google Scholar
  83. 83.
    Mishra SME, Pickles M, Vickerman P, Shastri S, Gilks C, Dhingra NK, Washington R, Becker ML, Blanchard JF, Alary M, Boily MC. Strategic Epi-ART in India Modelling Team, Exploring the population-level impact of antiretroviral treatment: the influence of baseline intervention context. AIDS. 2014;28(1):S61–72.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • K. M. Sileo
    • 1
    • 2
    Email author
  • R. K. Wanyenze
    • 3
  • W. Kizito
    • 4
  • E. Reed
    • 1
  • S. K. Brodine
    • 1
  • H. Chemusto
    • 4
  • W. Musoke
    • 4
  • B. Mukasa
    • 4
  • S. M. Kiene
    • 1
  1. 1.Graduate School of Public HealthSan Diego State UniversitySan DiegoUSA
  2. 2.Center for Interdisciplinary Research on AIDS at Yale UniversityNew HavenUSA
  3. 3.Makerere School of Public HealthMakerere UniversityKampalaUganda
  4. 4.Mildmay UgandaKampalaUganda

Personalised recommendations